Phase II trial of gemcitabine-carboplatin-paclitaxel (GCP) as neo-adjuvant chemotherapy for operable non-small cell lung cancer (NSCLC)

Authors :: R. P. Abratt
J. S. Lee
J. Y. Han
C. M. Tsai
M. Boyer
T. Mok
S. W. Kim
A. J. M. Brnabic
M. Lehnert
Source :: Journal of Clinical Oncology. 23:7260-7260
Publication Year :: 2005
Publisher :: American Society of Clinical Oncology (ASCO), 2005.
Abstract: 7260 Background: Randomized phase III trials suggest that neo-adjuvant cisplatin-based chemotherapy prior to surgery may improve survival in patients (pts) with operable NSCLC. The aim of this open...

Subjects :: Oncology
Cisplatin
Cancer Research
medicine.medical_specialty
Chemotherapy
Phase iii trials
business.industry
medicine.medical_treatment
non-small cell lung cancer (NSCLC)
medicine.disease
Carboplatin/paclitaxel
Gemcitabine
Internal medicine
Medicine
In patient
business
Neo adjuvant chemotherapy
medicine.drug

Full Text Access

Tools